Go Back

EANM Procedure Guidelines in Neuroimaging

On this page you will find links to some European Association of Nuclear Medicine (EANM) Procedure Guidelines relating to neuroimaging. The aim of these documents is to provide general information about the clinical procedures described. 

They are categorized in clinical applications. Please follow the links below to the desired applications. 

These guidelines summarize the views of the European Association of Nuclear Medicine
Neuroimaging Committee (ENC). The purpose of the guidelines is to assist nuclear medicine practitioners in recommending, performing, interpreting, and reporting the results of brain perfusion SPECT studies using 99mTc-labelled radiopharmaceuticals. The aim is to achieve a high quality standard of brain perfusion SPECT imaging, which can increase the diagnostic impact of this technique in neurological and psychiatric practice.

The purpose of the guidelines is to assist nuclear medicine practitioners in recommending, performing, interpreting, and reporting the results of F-18-fluoro-2-deoxyglucose (18FDG)-PET imaging of the brain. Aim is to help in achieving a high quality standard of FDG imaging, which allows to increase the diagnostic impact of this technique in neurological and psychiatric practice.

The purpose of the guidelines is to assist nuclear medicine practitioners in recommending, performing, interpreting, and reporting the results of radiolabelled amino acid analogues for PET or SPECT imaging of brain tumours.

These guidelines deal with the indications, assessment, processing, interpretation and reporting of dopamine transporter (DAT) SPECT investigations using the commercially available radiopharmaceuticals [123I]β-CIT and [123I]FP-CIT.

These guidelines deal with the indications, assessment, processing, interpretation and reporting of dopamine D2 receptor SPECT and PET studies using the commercially available radiopharmaceuticals [123I]-IBZM and [123I]-epidepride, as well as [11C]-raclopride, [18F]fallypride and DMFP.